Cycling Team Reaches $500,000 in Fundraising for the Alzheimer’s Association

Photo caption: Beginning top left to right: Andy Roberson, Brandon Granger, David Calder, Eric Calder, Louis Redmond, Rusty Copsey, Glen Calder and David Minnich. Second row standing: William Luce, Hugh McVeety, Phil O’Donnell, Jim Van Vleet, Matt Van Vleet, Geoff Christian, Jonathan Bachman, Morgan Alford, Andrew Howard and Gaines Huguley. Kneeling: Joe Parisi and Jim Malscheski. Front: Greg Muxlow and Chris Calder.

Cyclists sponsored by Calder Brothers Corporation, manufacturer of Mauldin Paving Products, recently participated in the 2024 “Ride to End ALZ” cycling event, raising $148,971 for the Alzheimer’s Association. The Calder Brothers team has now participated in eight consecutive Alzheimer’s cycling events, raising a total of over $568,781 over the eight-year period.

The scenic, three-day journey across the state of South Carolina began this year on July 12 in Simpsonville, and over 400 cyclists completed the 257-mile journey on Sunday, July 14, in Mount Pleasant. This year’s Ride to End ALZ raised over $1.2 million for the Alzheimer’s Association.

“Our team was formed to honor my dad, the late Robert Calder, who passed away in 2014,” explained Calder Brothers Executive Vice President Glen Calder. “It was an honor to ride in his memory and others who have lost loved ones. My wife is currently struggling with early onset dementia, and we are living with the challenges of this disease every day.”

“The efforts of our volunteers and cyclists, like the Calder Brothers team, are simply amazing,” shared Jerry Chapman, Director of Ride to End ALZ South Carolina. “It’s encouraging considering that eight years ago, there were no options for the treatment of Alzheimer’s. Thanks in part to this event and the efforts of all involved with the Alzheimer’s Association, we now have several FDA-approved treatments showing positive results in slowing the decline of this terrible disease.”

The mission of the Alzheimer’s Association is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.